Pseudorabies virus 10345 After natural infection, the primary site of viral replication is nasal, pharyngeal, or tonsillar epithelium. The virus spreads via the lymphatics to regional lymph nodes, where replication continues. Virus also spreads via nervous tissue to the brain, where it replicates, preferentially in neurons of the pons and medulla. In addition, virus has been isolated from alveolar macrophages, bronchial epithelium, spleen, lymph nodes, trophoblasts, embryos, and luteal cells (Merck Vet Manual: Pseudorabies). Aujeszky's disease Although the pig is the only natural host, the virus can infect cattle, sheep, cats, dogs, and goats as well as wildlife, including raccoons, opossums, skunks, and rodents. Experimental studies in nonhuman primates indicate that rhesus monkeys and marmosets are susceptible but chimpanzees are not. Reports of human infection are limited and are based on seroconversion rather than virus isolation. Infections in horses are rare (Merck Vet Manual: Pseudorabies). Pseudorabies is a viral disease in swine that is endemic in most parts of the world. It is caused by porcine herpesvirus 1, which is also called pseudorabies virus (PRV) or suid herpesvirus-1 (SHV-1) and is also known as Aujeszky's disease, and in cattle as mad itch. PRV is considered to be the most economically important viral disease of swine in areas where hog cholera has been eradicated. Other domestic and wild mammals, such a cattle, sheep, dogs, raccoons are also susceptible. The disease is usually fatal in these hosts. The virus is shed in the saliva and nasal secretions of infected swine and is spread through oral or nasal contact. Aerosolization of the virus and transmission by fomites also may occur. The virus may potentially survive for seven hours in humid air and spread up to two kilometers. Furthermore, it may survive on well water for up to seven hours, in green grass, soil, and feces for up to two days, in contaminated feed for up to three days, and in straw bedding for up to four days (Wiki: Pseudorabies). Baboon Papio cynocephalus 9556 Bank vole Clethrionomys glareolus 447135 Bear Ursus americanus 9643 Birds Passeroidea 175121 Brown Trout Salmo trutta 8032 Buffalo Bison bison 9901 Carnivores Vulpes 9625 Cat Felis catus 9685 Catfishes Siluriformes 7995 Cattle Bos taurus 9913 Chicken Gallus gallus 9031 Chimpanzee Pan troglodytes 9598 chinchillas Chinchillidae 10150 Copper Pheasant Syrmaticus soemmerringii 9067 Deer Cervus elaphus 9860 Deer mouse Peromyscus maniculatus 10042 Dog Canis familiaris 9615 Ducks Anas 8835 Ferret Mustela putorius furo 9669 Fish Hyperotreti 117565 Gerbil Gerbillina 10045 Goat Capra hircus 9925 Gray wolf Canis lupus 9612 Guinea pig Cavia porcellus 10141 Hamster Mesocricetus auratus 10036 Horse Equus caballus 9796 Human Homo sapiens 9606 Macaque Macaca fascicularis 9541 Mongolian Gerbil Meriones unguiculatus 10047 Monkey Platyrrhini 9479 Mouse Mus musculus 10090 None None Parrot Psittacidae 9224 Pig Sus scrofa 9823 Rabbit Oryctolagus cuniculus 9986 Rainbow trout Oncorhynchus mykiss 8022 Rat Rattus 10114 Raven Corvus corax 56781 sei whale Balaenoptera borealis 9768 Sheep Ovis aries 9940 Squirrel Spermophilus richardsonii 37591 Tree shrew Tupaiidae 9393 Trouts, salmons & chars Salmoninae 504568 Turkey Meleagris gallopavo 9103 Vole Microtus ochrogaster 79684 Water buffalo Bubalus bubalis 391902 NYVAC-PRV- gII/ gp50 VO_0004778 Recombinant vector vaccine Research Intramuscular injection (i.m.) (Brockmeier and Mengeling, 1996) A NYVAC vaccinia vector containing genes for PRV gII and gp50 . Intramuscular injection (i.m.) Recombinant vector construction A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 (Brockmeier and Mengeling, 1996). Recombinant vector construction A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 (Brockmeier and Mengeling, 1996). The pigs were vaccinated via intramuscular injection in the thigh with 10^7 CCID50 of NYVAC/gp50 or NYVAC/gpII,gp50, 4 weeks apart (Brockmeier and Mengeling, 1996). VO_0003057 Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge (Brockmeier and Mengeling, 1996). Vaccinated pigs were challenged with 10^8 PFU of Indiana-Funkhauser strain of PRV oronasally, 4 weeks after the second vaccination (Brockmeier and Mengeling, 1996). Pseduorabies Subunit Glycoprotein C Vaccine VO_0004155 Subunit vaccine Research Intramuscular injection (i.m.) ISA-70 oil adjuvant Intramuscular injection (i.m.) Recombinant protein preparation Psuedorabies glycoprotein C was purified from pseudorabies infected cell lysates (Katayama et al., 1997). Pigs of each group were immunized intramuscularly with one ml of the different trial vaccines at two week intervals. Control pigs were vaccinated with unifected cell lysate antigens (Katayama et al., 1997). Immunized pigs had a high (87.5%) rate of survival against lethal PRV challenge (Katayama et al., 1997). One week after immunization pigs were challenged intranasally with 10^6 TCID50 of PRV Yamagata S-81 strain (Katayama et al., 1997). Pseudorabies Modified Live Virus Vaccine (USDA: 1891.20) Wyeth, Boehringer Ingelheim Vetmedica, Inc., Pfizer, Inc. VO_0001806 Live, attenuated vaccine Licensed USA Pseudorabies Modified Live Virus Vaccine (USDA: 1891.22) Pfizer, Inc. VO_0001807 Live, attenuated vaccine Licensed USA Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R2) Intervet Inc. VO_0001808 Live, attenuated vaccine Licensed USA Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R4) Intervet Inc. VO_0001809 Live, attenuated vaccine Licensed USA Pseudorabies recombinant vector vaccine encoding gp50 and gII protein VO_0004156 Recombinant vector vaccine Licensed NYVAC vaccinia vector [Ref1255:Brockmeier and Mengeling, 1996]. Intramuscular injection (i.m.) Intramuscular injection (i.m.) Recombinant vector construction Recombinant vector construction 4-6 wk old male pigs from a PRV negative herd were vaccinated intramuscularly with two injections in the thigh of 10^7 CCID50 of NYVAC/gp50gpII 4 weeks apart. The control group was not vaccinated (Brockmeier and Mengeling, 1996). Vaccinated pigs were protected from PRV challenge (Brockmeier and Mengeling, 1996). Challenge consisted of administering 10^8 PFU of Indiana-Funkhauser strain of PRV oranasally, 4 weeks after the 2nd immunization (Brockmeier and Mengeling, 1996). Pseudorabies recombinant vector vaccine encoding gp50 protein VO_0004003 Recombinant vector vaccine Research NYVAC vaccinia vector [Ref1255:Brockmeier and Mengeling, 1996]. Intramuscular injection (i.m.) Intramuscular injection (i.m.) Recombinant vector construction 4-6 wk old male pigs from a PRV negative herd were vaccinated intramuscularly with two injections in the thigh of 10^7 CCID50 of NYVAC/gpSO 4 weeks apart. The control group was not vaccinated (Brockmeier and Mengeling, 1996). Vaccinated pigs were protected from PRV challenge (Brockmeier and Mengeling, 1996). Challenge consisted of administering 10^8 PFU of Indiana-Funkhauser strain of PRV oranasally, 4 weeks after the 2nd immunization (Brockmeier and Mengeling, 1996). Pseudorabies Subunit gB Protein Vaccine VO_0004041 Recombinant vector vaccine Research Replication-incompetent adenovirus [Ref1250:Han et al., 2008]. Intramuscular injection (i.m.) Intramuscular injection (i.m.) Recombinant vector construction C57BL/6 Groups of female mice were immunized with replication-incompetent adenoviruses expressing PrV glycoprotein (rAd-gB) by either the intranasal (i.n.) or intramuscular (i.m.) route. For i.m. administration, recombinant adenoviruses (10^6 pfu/mouse) were injected into the anterior tibialis muscle three times at weekly intervals (0, 7, and 14 days). The i.n. immunizations were also performed three times at weekly intervals (0, 7, and 14 days) by depositing 10^6 pfu of recombinant adenovirus onto the nares of deeply anesthetized mice. Control mice were immunized with replication-incompetent adenovirus expressing the LacZ gene (rAd-LacZ) (Han et al., 2008). Recombinant adenovirus expressing gB (rAd-gB) was found to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route (Han et al., 2008). The immunized mice were infected i.n. with the virulent PrV YS strain (10 LD50) two weeks after the final immunization. The challenged mice were examined daily to quantify the number of dead animals. Mice generally began to exhibit clinical signs of illness 3 to 4 days post-challenge (Han et al., 2008). In splenocytes and popliteal lymph node cells, IL-2 was induced to a significantly higher level in immunized animals as compared to replication-incompetent adenovirus expressing LacZ (rAd-LacZ) vaccinated mice. These elevated levels were detected 2 weeks after the final immunization (Han et al., 2008). In splenocytes and popliteal lymph node cells, IL-4 was induced to a significantly higher level in immunized animals as compared to replication-incompetent adenovirus expressing LacZ (rAd-LacZ) vaccinated mice. These elevated levels were detected 2 weeks after the final immunization (Han et al., 2008). In splenocytes and popliteal lymph node cells, IFN-gamma was induced to a significantly higher level in immunized animals as compared to replication-incompetent adenovirus expressing LacZ (rAd-LacZ) vaccinated mice. These elevated levels were detected 2 weeks after the final immunization Pseudorabies Subunit gI Protein Vaccine VO_0004040 Subunit vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) Recombinant protein preparation C57BL/10 For active immunization mice were injected i.m. (hind leg) with different concentrations of emulsified purified (by electroelution) fusion protein (Fuchs et al., 1990). Vaccination of mice with fusion proteins containing the N terminus of gI from Suid herpesvirus 1 are able to confer protection to mice against a lethal challenge of PRV (Fuchs et al., 1990). Twenty-four h later the animals were infected intramuscularly (i.m.) into a hind leg using 0-1 ml of a lethal dose ( > 100 LD50) of strain Phylaxia, and the mice were observed for at least 10 days (Fuchs et al., 1990). Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine VO_0002983 Live, attenuated vaccine Research intranasal immunization intranasal immunization Gene mutation This glycoprotein E/G/UL23 mutant is from Suid herpesvirus 1 (Weigel et al., 2003). Gene mutation This glycoprotein E/G/UL23 mutant is from Suid herpesvirus 1 (Weigel et al., 2003). Gene mutation This glycoprotein E/G/UL23 mutant is from Suid herpesvirus 1 (Weigel et al., 2003). A glycoprotein E/G/UL23 is attenuated in raccoons (Weigel et al., 2003). A glycoprotein E/G/UL23 mutant provides some protection in raccoons from challenge with wild type Pseudorabies virus (Weigel et al., 2003). Pseudorabies virus gp50/gp63 mutant vaccine VO_0002986 Live, attenuated vaccine Research Intramuscular injection (i.m.) Intramuscular injection (i.m.) Gene mutation This gp50/gp63 mutant is from Suid herpesvirus 1 (Peeters et al., 1994). Gene mutation This gp50/gp63 mutant is from Suid herpesvirus 1 (Peeters et al., 1994). A gp50/gp63 mutant is attenuated in pigs (Peeters et al., 1994). A gp50/gp63 mutant vaccine induces protection in pigs from challenge with wild type Pseudorabies virus (Peeters et al., 1994). Pseudorabies virus UL50 mutant vaccine VO_0002989 Live, attenuated vaccine Research intranasal immunization intranasal immunization Gene mutation This UL50 mutant is from Suid herpesvirus 1 (Jöns et al., 1997). A UL50 mutant is attenuated in pigs (Jöns et al., 1997). A UL50 mutant induces protection in pigs from challenge with wild type Pseudorabies virus (Jöns et al., 1997). Pseudorabies virus US3 mutant vaccine VO_0002990 Live, attenuated vaccine Research intranasal immunization intranasal immunization Gene mutation This US3 mutant is from Suid herpesvirus 1 (Kimman et al., 1994). A US3 mutant is attenuated in pigs (Kimman et al., 1994). A US3 mutant induces complete protection in pigs from challenge with wild type Pseudorabies virus (Kimman et al., 1994). Psuedorabies DNA vaccine encoding IE180 protein VO_0004039 DNA vaccine Research pcDNA3.1 [Ref1246:Chang et al., 1998] Gene Gun Gene Gun DNA vaccine construction BALB/c, C3H/HeJ, and C57BL/6 Two shots of DNA/mouse (1 /Ag/shot) were delivered with helium at 200 psi via the Helios Gene Gun to the shaven abdominal skin of 10 male mice of each strain, BALB/c, C57BL/6, C3H/HeJ. The mice received a booster once 14 days later with the same dose of DNA. In some experiments, pregnant mice of each strain were vaccinated immediately before mating and a booster was given 2 weeks later (Chang et al., 1998). Seven months after immunization with pcDNAIE180, an overall 25% of BALB/c, C3H/HeJ, and C57BL/6 mice receiving a lethal PrV challenge were protected (Chang et al., 1998). Six months after second vaccination, groups of pcDNAIE180 immunized mice were challenged intraperitoneally with a precalibrated mouse acute lethal dose of wild-type PrV-Ka TK+ (15 plaque-forming units (PFU)/g of body weight). The challenged mice were observed three times daily for clinical signs, and percent survival was assessed within 4 to 5 days postchallenge (Chang et al., 1998). Psuedorabies virus glycoprotein M mutant vaccine VO_0002985 Live, attenuated vaccine Research intranasal immunization intranasal immunization Gene mutation This glycoprotein M mutant is from Pseudorabies virus (Dijkstra et al., 1997). A glycoprotein M mutant is attenuated in piglets (Dijkstra et al., 1997). A glycoprotein M mutant induces protection in piglets from challenge with wild type Pseudorabies virus (Dijkstra et al., 1997). rORFV-PRV-gC/gD VO_0004770 Recombinant vector vaccine Research Intramuscular injection (i.m.) Based on the attenuated ORFV strain D1701-V, recombinants were produced that express the glycoproteins gC (D1701-VrVgC) or gD (D1701-VrVgD) of the alphaherpesvirus of swine, pseudorabies virus (PRV) (Fischer et al., 2003). Intramuscular injection (i.m.) Mice were injected intramuscularly (i.m.) with 107 TCID50s of the ORFV recombinants expressing the PRV glycoproteins in a total volume of 0.2 ml (0.1 ml for each hind leg). Immunization was repeated at 2-week intervals (Fischer et al., 2003). VO_0003057 Single or combined immunization with the ORFV recombinants protected different mouse strains of a host species nonpermissive for ORFV against a fulminant, lethal PRV challenge infection equal to immunization with PRV live vaccine. Most notably, even a single immunization with D1701-VrVgC was protective, whereas two applications of D1701-VrVgD were required for immune protection (Fischer et al., 2003). Mice were challenge infected intraperitoneally (i.p.) with 10^2 PFU of the highly virulent PRV strain NIA-3, and the C57BL/6 and 129/Sv/Ev mice were infected with 10^3 PFU Suvaxyn Aujeszky Suvaxyn Aujeszky Fort Dodge VO_0000936 Inactivated or "killed" vaccine Licensed Intramuscular injection (i.m.) gE- and thymidine kinase-deleted marker vaccine(Ferrari et al., 2000) Intramuscular injection (i.m.) gB Suid herpesvirus 1 VO_0011238 4138504 UniProtKB/TrEMBL:Q9WJ33 10345 16807 19721 - envelope glycoprotein B 3.29 1207.11 60 strains Kaplan (Ka), Becker (Be), Rice, Indiana-Funkhauser (In-Fh), NIA-33 and TNL >CAA09075.1 gB, partial [Suid alphaherpesvirus 1] ESEDPDAL Protective antigen Recombinant adenovirus expressing gB (rAd-gB) was found to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route [Ref1250:Han et al., 2008]. GI Suid herpesvirus 1 VO_0011251 255957222 CDD:177577 CDD:165547 10345 ? envelope glycoprotein gI 9.1 35302.37 440 envelope glycoprotein I; Provisional >ACU43467.1 envelope glycoprotein gI, partial [Suid alphaherpesvirus 1] RDVTRLPAGLLLAALTLAALTPRVGGVLFRGAGVSVHVAGSAVLVPGDAPNLTIDGTLLFLEGPSPSNYS GRVELLRLDPKRACYTREYAAEYDLCPRVHHEAFRGCLRKREPLARRASAAVEARRLLFVSRPAPPDAGS YVLRVRVNGTTDLFVLTALVPPRGRPHHPTPSSADECRPVVGSWHDSLRAVDPAEDAVFTTQPPPEPEPP TTPAPPRGTGATPEPRSDEEEEDEEGATTAMTPAPGTLDANGTMVLNASVVSRVLLAAANATAGARGPGK IAMVLGPTIVVLLIFLGGVACAARRCARNRIYRPRPGRGPAVHAPPPRRPPPSPVAGAPVPQPKMTLAEL RQKLATIAEEQ Protective antigen Vaccination of mice with fusion proteins containing the N terminus of gI from Suid herpesvirus 1 are able to confer protection to mice against a lethal challenge of PRV [Ref1258:Fuchs et al., 1990]. GII Suid herpesvirus 1 VO_0011249 1335775 CDD:223014 10345 ? glycoprotein gII 11.38 14546.78 200 glycoprotein BALF4; Provisional >AAB26946.1 glycoprotein gII, partial [Suid alphaherpesvirus 1] PFGALAIGLLVLAGLVAAFLAYRHISRLRRNPMKALYPVTTKALKEDGVEEGDVDEAKLDQARDMIRYMS IVSALEQQEHRRARRTAGPRSWPAGSGRWLRAAGTTSASRARTPTPCSPLPRETIKMRLFGNT Protective antigen A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [Ref1255:Brockmeier and Mengeling, 1996]. glycoprotein E Suid herpesvirus 1 307634504 CDD:177575 CDD:190321 10345 ? glycoprotein E 578 envelope glycoprotein E; Provisional >gi|307634504|gb|ADN78283.1| glycoprotein E [Suid herpesvirus 1] MRPFLLRAAQLLALLALALSTEAPSLSAETTPGPVTEVPSPSVEVWDDLSTEAGDDDLNGDLDGDDRRAG FGSALASLREAPPAHLVNVSEGANFTLDARGDGAVLAGIWTFLPVRGCDAVSVTTACFETACHPDLVLGR ACVPEAPEMGIGDYLPPEVPRLRREPPIVTPERWSPHLSVLRATPNDTGLYTLHDASGPRAVFFVAVGDR PPAPADPVGPARHEPRFHALGFHSQLFSPGDTFDLMPRVVSDMGDSRENFTATLDWYYARAPPRCLLYYA YEPCIYHPRAPECLRPVDPACSFTSPARARLVARRAYASCSPLLGDRWLTACPFDAFGEEVHTNATADES GLYVLVMTHNGHVATWDYTLVATAAEYVTVIKELTAPARAPGTPWGPGGGDDPIYVDGVTTPAPPARPWN PYGRTTPGRLFVLALGSFVMTCVVGGAVWLCVLCSRRRAASRPFRVPTRARTHMLSPVYTSLPTHEDYYD GDDDDEEAGVIRRRPASPGGDSGYEGSYASLDPEDEFSSDEDNGLYVRPEEAPRSGFDVWFRDPEKPEVT NGPNYGVTANRLLNARPA Virmugen A glycoprotein E mutant, in combination with UL23 and glycoprotein G mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV [Ref1962:Weigel et al., 2003]. glycoprotein G Suid herpesvirus 1 15422177 CDD:186820 10345 ? glycoprotein G 499 Herpesvirus glycoprotein D/GG/GX domain; cl08328 >gi|15422177|gb|AAK95859.1| glycoprotein G [Suid herpesvirus 1] MKWATWILALGLLVVRTVVAREAPRELCYGHPVHDDRRPVGPATDAQPVNPLAPANATGTDYSRGCEMRL LDPPLDVSSRSSDPVNVTVAWFFDGGHCKVPLVHREYYGCPGDAMPSVETCTGGYSYTRTRIDTLMEYAL VNASLVLQPGLYDAGLYIVVLVFGDDAYLGTVSLSVEANLDYPCGMKHGLTITRPGATLPPIAPTAGDHQ RWRGCFPSTDEGAWENVTAAEKGLSDDYADYYDVHIFRLESDDEVVHGDAPEAPEGEEVTEEEAELTSSD LDNIEIEVVGSPAAPVEGAGDGEEGHGDEEDEELTSSDLDNIEIEVVGSPAAARFFAASTTPRAPTRAAE ITTMTTVTTVRTTEDPSGITDCRRSDFVSPSDIFVTPTGSPALLLGFLGSALASRPLHLTAGETAQHVRE AQQKSRHVRSLGGLQLSVETETTNTTTTQTGLSGDIRTSIYICVALAGLVVVGIVIMCLHMAIIRARARN DGYRHVASA Virmugen A glycoprotein G mutant, in combination with UL23 and glycoprotein E mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV [Ref1962:Weigel et al., 2003]. glycoprotein M 1478255 CDD:177566 GOA:Q85041 InterPro:IPR000785 UniProtKB/Swiss-Prot:Q85041 33703 ? UL10 525 envelope glycoprotein M; Provisional >gi|1478255|emb|CAA65905.1| UL10 [Suid herpesvirus 1 strain Kaplan] MTYASESKYVTNPRPASSIRLARVRVKLRRQDRTSALISVAASAAESHFSSAVVLPEPIGARATRTRRQA VSCGDGSSTGASRCRSRETPGQRLRTTAGRSQPYSIRASDTLEANAPPSSSAPPRRPPASAAMCGPRNAE AVSWRSWLIEVCGFALAALTLVLTLIFASLPEMGFPCFYATVADYDTLNDTSGGVWTRQPLVAPALFLET PTVTSFFGFTATVLLAHALYAVAGAVVLRREAGRLAFQPSVVLYAASTVAAPGTLMLGALCAWTLQAVVL LMAHKQAGLAAAAYITHFVFLALFGACHACKGTGDVRAALAASPPLRRVAVHARAVVTNVVLGAVGLGAA VVGLMLGVLLANSFHISLWKTAEAALAVFTLLALALMVFVEVVVSGYVQVLPTPAFCVLVASAAFGVSAH RYFAKFSEALGETHGVVIGTRAVLAVLSLIALAMIVVRLVRACIAHRARGSRFYANVDKARTTARRYLQK RLHGRGNDEYLLAPGSGDDEFDDGDEVVYENLGFE Virmugen A glycoprotein M, gM, deletion in pseudorabies virus was attenuated and induced protection in piglets against intranasal challenge with 10^8 p.f.u. of the highly virulent PrV strain NIA-3 ([Ref1970:Dijkstra et al., 1997]. gp50 Suid herpesvirus 1 VO_0011248 2440155 CDD:279830 InterPro:IPR002896 UniProtKB/TrEMBL:O41201 10345 ? glycoprotein gp50 5.27 25087.4 307 isolated from camels >CAA75105.1 glycoprotein gp50, partial [Suid alphaherpesvirus 1] MLLAALLAALVARTTLGADVDAVPAPTLPPPAYPYTESWQLTLTTVPSPFVGPADVYHTRPPEDPCGVVA LISDPQVDRLLNEAVAHRRPTYRAHVAWYRIADGCAHLLYFIEYADCDPRQIFGRCRRRTTPMWWTPSAD YMFPTEDELGLLMVAPGRFNEGQYRRLVSVDGVNILTDFMVALPEGQECPFARVDQHRTYKFGACWSDDS FNGGVDVMRFLTPFYQQPPHREVVNYW Protective antigen A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [Ref1255:Brockmeier and Mengeling, 1996]. gp50 Suid herpesvirus 1 2952548 51557533 SuHV1_gp50 BK001744 YP_068367 10345 83052 86540 + 9.08 46944.96 470 >gi|51557483:83052-86540 Suid herpesvirus 1, complete genome CATGTTCGCCTACGTGAAGCCGATGGCGCACGGCCCGGACATGGCCTCCGTCTACCAGTCCACGGGGCGC GTGCGGCGGCTGCTGCGCGACGAGCTCTTCGTGTACGTGGACGGCTCCGGCGCGCGCGGCGAGCCCATCT TCACGCCCGTGCTGCTGAACCACGTCGTGGGCTCGGGCTGGCCGGCGCGCCTGTCGCAGGTGACGAACCT CGTGTGCGCGCAGTTCCAGCGCCGCTGCCGCCCGGCGTTCGCGGCGGCGCGCGGGATGCGCCTCTTCTCC CGCTTCAAGTTCAAGCACCTGTTCGAGCGCTGCACGCTGACGAGCGTCAACGACAGCCTCAACATCCTGC ACGCGCTGCTGGAGAACAACCGCCTGCGGGTGGCGCTCGAGGGCTGCGAGCCGCCGCTGACGGCGCGCGC CTTCTGCGACTTTCTGCGCGACGCGCGCCTGGACGCCTTCGCCAGCCAGCAGGTGCTGCGGCAGCTGCGC CCCCCGGACCGGCCGGTGGCGGCCGACATCGCGGACAGCGGCGAGGTGGCCACCTTCGTGGAGAAGTACC TCGTGGCCGACGTGCCCGAGGACGAGCTGCAGGAGCTGCTGCGCGCGCTCGCCAACCCCGTGACGCGGGA GCAGTTTGTGGGCCTGGCCGTGCTCGGCGCGTGCGCGCGCGTCCCCGAGGCGCTGCGCAGCGAGCGCGTC TTCGGGGCCGTGTACGGGCACTACGCCTCCGGGGCCGTGCCCGTGGTGGCCGACGGGCGGCTGGAGCTGG CGGCGCTGGCCCCCGACTTCAACGTGCCCGCGCGCTGGGCCCTCACGCGGCGCTGCGCGCGCGTCGCGGA GGCCGCCGGGCTCTTCGAGGGCGCCTCGCCGGAGGTGGACTCGGCCGCGGTCGCGGCGGCGGCGGCCGAC GCCGAGCTGGCGCCGCTGCTGCTCGAGGTGCTGCGGTGCCACGTGCTGGACGCGACGACGGCCGCGCGGC GCCCCGTGCGCGCGGCCCTGAGCGCGCTGGGGGCGGGCGGGGGCGCGGGCCCGCTGAGCCGCGGGCGCCA CGCCGCGCTCGTGTTCAAGGTGATGTGGGAGGAGGCCTTCGGCGTGCGCGTCGGCCGCAGCCGGCAGACG TTCCCGGGGCCCACGCGCGTGAAGAACCTGCGCAAGGCCGAGATCGCCGCGCTGCTGCGCGACGCCGGCC TGGACCCGCCCGCGGGCGCCACCCACCGGCAGCTGTACGCCCTGCTGATGGAACGCCGGGGGGACTTTGC GGGGGAGAGGTATAAACTGCGCCTGCCCGCCTGGAGCCGGCTCATGTACCTGACCCAGGGCGGCTTCGAC GCGCCGCTGGACGCCGCGCTCTCGCTCGTGCCCGCGGAGGCGTGGCCGCGCACCGAGGGGGCCGTGGACT TTGCGGCGCTATGACGGCCGCGGCGGGGGAGCGCGTGTGCGCGGCCGGGATCTACACGGCCTGGACGGAG CCCGGCGCGCCGGGCGAGCTCCACGCGCTGGCGCACCTGCTGTGCCGCGACGGGGCCGGCGCGTACGCGG CGCGCTTCGTCCACGTGACGGCGGCGCCGTGGACGGGCTCGGCGGCCGCGGTGGCCGCGGCGCTGCGCGA CGCGAGCGGCACGGGGGCGCTGGCGGACCCGGCGCTGTGGCGCGGCGCGCACGGCGCGGTCATGGCGGCC CTGCGCCGCGCCCTCCCGGCGCTGGCCTTCTACGAGCCGCTGCGCTTCGAGACGGACCCGGCCACGAACC TGGTCACGGCCGCGACGCCGGCGGGCGGCGGCGGCGAAGAGGAGACGACCGGGGAGGGCGGCGAGGAGGA CGAGGACGAGGCCGGCCCGCGCGCGGGCATCATCCACGTGGACGCCGACGTCGTCGTGGACCGCGACGCC GCGCGCGCGCACGCCACCGAGGCGTGGCTGCCGCACGCCCAGCTGCGCGCCATGGCCGGCTGCGCCGCGC TCTCCGTCGAGATCACGACGCGGCGGACCAGCTTCGCGCGCGCCTACGCGGAGGCCGGCGCGCCGCCGCT GAAACGCCGGGGCGAGATGAGCGACCCCTTTGACGTGCGCGAGACGGTGCTGCGGCCCGCGGGCCGGCGC GTGGCGGCGCGCGTGCTCGTCCCGCGCGGCTTCGACTGCCTGGTGGCCCACGGCGTGAGCAACGCGGCGC TGGTGGCGCTCTACCGCCGGTGGCACGCGGCCGCGTACGGCGCGGGCGACGCGACCCCGCCCGTCTTCGC CTTCCTGGGGCCCGAGCTCGCCCGCGAGGGCGCGGACGAGGACTACTACTGCGCGCTGGGCTTCCCCCTG TTTGCGACGATCAAGGTGGCCGCGGCCGCGCCGGAGGCGGTCCGCGGCGCGCTCGCCGCCCACCGGCTCA CGGACGGGCTGTGGCCCGCGCTCGGCTTCCGCGCCTTCCACGCCCTCGGGCCCGTGAGCTGCGGCCTGCG CCTGCGCTGCGACGTCTGGCCGGCGGGGCGCGCGACCAGCGCCGTGGAGCACCCGTGCGCCCTCCGCGGG GCCTGGCTGGCCAAGTTTGACTTCGCGGCCTTCTTCCCCAACCTGTTTCTGGCCCTGTGCCCGGGCCACG AGCGGCTGCGGCGCGCCGTGCGGGCGCGCGCGGTCAAGCCGGCGCTCGTGGCCTTCTTCGGCGGGCTCAA GCACACGTGCCCGGAGGCGTACCACAGCGTCATCGCGCTGGCCAACGGGGTCTCGCGCGCCGTCGAGGCG GCCGCGGCCGAGGCCGGCCTGGTCACGTGCGCCTACGTCAAGGACGGCTTCTGGGGCGTGCTCGGCGACG TGCCCGCGGCCGCGCCGGAGGCGGCCGCCGCCGCCGCGGCCGAGCGCGTGCGCGTCGCCTGCGAGGCCGC CGCGGCGCGGCACCTGGCCGACGCGGGGGCCGCCGCGACGGACGTGACGCTGCGCTGCGAGGGCGTCTTC GACGCGGCCCTGGCCTGGTCCTGCCACGCCTACTGGCTGCGGCGGCGCGAGGGCCCCGCGGACTTTGTCG GCTTCCCGTCGCGCAGCGGCTTCGGCCGCGCCGCCAAGGCCGCGCTGGACGCCCTGCTGCGCGAGGCCGT CGAGGGCCGCGCGGACGCCGAGGCCGCGCGCGCCGCCTGCGACGGCCTCGTCGAGCGGGCCTTCGCCTCG CGCCACGACCCCGACTTCTGGGCCGCGCCGGGGGACGCCCTCGCCCCCGCCGCGTGCGCAGGGGCGACCG CCGGGCGCGGCGGCGCGCGCTGCTCGCGGCGCTGCGTGCGCCTGCGCGGCGCCGGCCCGGTGCCCTACGA GCAGCTGCGCCCCCCGCTGATCCTGCCCTGGATAGACTGTCTGGCCCACATGGAGCCCATCTTCGCCGCC CTCGTCGGCATGTACAACCGCGCGCTCGAGGCGCTGAGCGCCGGCGACGCCCCGCCGCCATTTGTGTTTA CATACACGCCGGACGCGTTTCTGTTTGGGTAAACAATAAAGTCTGTTTATTGTCAGAAC >gi|51557533|ref|YP_068367.1| UL8.5 protein [Suid herpesvirus 1] MFAYVKPMAHGPDMASVYQSTGRVRRLLRDELFVYVDGSGARGEPIFTPVLLNHVVGSGWPARLSQVTNL VCAQFQRRCRPAFAAARGMRLFSRFKFKHLFERCTLTSVNDSLNILHALLENNRLRVALEGCEPPLTARA FCDFLRDARLDAFASQQVLRQLRPPDRPVAADIADSGEVATFVEKYLVADVPEDELQELLRALANPVTRE QFVGLAVLGACARVPEALRSERVFGAVYGHYASGAVPVVADGRLELAALAPDFNVPARWALTRRCARVAE AAGLFEGASPEVDSAAVAAAAADAELAPLLLEVLRCHVLDATTAARRPVRAALSALGAGGGAGPLSRGRH AALVFKVMWEEAFGVRVGRSRQTFPGPTRVKNLRKAEIAALLRDAGLDPPAGATHRQLYALLMERRGDFA GERYKLRLPAWSRLMYLTQGGFDAPLDAALSLVPAEAWPRTEGAVDFAAL Virmugen A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3 [Ref1980:Peeters et al., 1994]. gp63 Suid herpesvirus 1 2952540 51557548 SuHV1_gp63 BK001744 YP_068382 10345 102695 107803 - transcriptional regulator ICP4 8.04 141692.15 1446 >gi|51557483:102695-107803 Suid herpesvirus 1, complete genome CAGAAAATACAGCACAAACTTTATTTTCTCACTCTGAAAACAAACTCTTTTCTCACCCGATGGGAGAAGG AGGAGAAGGGGACCGGGGGACCGCGGGAGGAGGAGAAGGGGACCGGGACGATCCTCCGCCGCCGAGCCCT CCGCCGCGGCCGCCGCCGCCGCTTCCACCACCGCCGCCACCTCCGCCGCCGCCGCAGCCACCTCCGGCCG GGGGATCCGCGCGGAGGAGAAGGAGAGGAGGAGGGCCACCGGGCCGGGGAGGCAGGCGCCGGGGAGGCAA GCGCCGCCGGGCCGAGGGGACCGAGGCCGCCGCCGCGGACGCAGAGGAGGAGGAGGACGGGGACGGGGAC GAGGACGAGGACGAGGACCGGGCCGAGGGCGAGGGGAGAGAAGACGGAGGAGAAGGGCCTCGAGGAGCCG GTGGAGGGGCCGGAGAGTCAGAGTCAGAGTCCGGCCGGGCCGAGGGGGCGCCCCGCTCAGCGGAGCAGCA GGTAGGGGTTGCCGGCGTCCTCGGCCTCCTCGTCGTCCGAGATGGCCTCCACCTTGATGGGCCCGAGCGG GCCGCGGGGCCGGCCGTCGCCGCCGCGGACGCCGACGATCTCCACAGAGTCCCCGTCCTCGCCGGGGCCG GCCCCGGCGCCCGAGGCCCCCGCGGGCCGGTGGGTCTCCACGGCGCCCCCGGCGGCGGCGCGGACGCTGG TCTCGAAGGGGGCAAAGTCCCAGAGCACGGCCGGCGGGGCGCCCGCGGCGGCGACGGCGCCCGGGGTCAG CACCAGCGGGGCGGCCTCGGCGTCGGGCTCCAGCAGCGCCGCGGCGCAGAAGGCGCGCAACTCGGCCGGC AGGCCCTCGGGGCCGCGGAGCTCGGCGAGGCCCCGGCGGCCGCAGGAGACGAAGACGGGCCGCAGCGGGG CGCCGAGCCCCCAGCGGTTGGCCGCGCGGTGCCCGAAGGCGGCGCCCGCGTCAAAGTCCGGGTCCCCGAG CCCGAGCGCGGAGCGCTGGCGGGCCATGTCCTTGCAGCCGTCCACGGTGGGGAGCACGCGCTGGCGGTAG GCGCGCGGCGGCAGCGGGACCGGGGTCCGGGGCCCGGCGCGGGTGCTCACCGTGTAGCGCACGTTGTCCT GGCGGCAGAGGCGCAGCGGCTCGGCCCCGGGGTGCAGGCGGGCGAAGGAGGCCTCCACGCGGGCGAAGCA GGCCGGGCCCACGATGGAGCTAGAGTCCAGCACGGCCGCGCGGAGCTCGCGGCACCCGGGCCAGCGCACG GCGCACTGGGCGGCCGGGTCCAGGCGGACGCGGACGTAGACGTGGTAGTCCCCCACGGCCGGGCCGTCCG CGGGCCAGTCCTCGATGGTGTCCAGCACGATGAGCCGGCGCCGCGCCGCGCCGAGCCGCGAGCAGAGGTA CTCCACGGCGCCGGCGAAGCCGAGGTCCCGCGCCGAGAGCAGCAGCACCCCCTGGGCGTTGAGGCGGCCG ATGTCGGGGCGCCCGGTCCAGTTCCCGGCCCAGGCGTGCGAGTCCGGCGTGCAGAGGCGGTGGGCGAAGG CGGCGAGCAGCGCCGAGAGGCCGCCGCGGCGCGGGTCCCAGGCCGGGCGCGGGGCGCCCTCGGCGGGCTC GGCGCAGAGCTCCTCGTGGGGCAGCGGGTCGTAGAGCACCACCACGCGCACGTCCTCGGGGTCGGCTATC TGCCGCATCCAGGCGGCGCGGCGGCGGAGCGGGGCGCCGCGGCGCGCGGCGATGTGCGCCAGGGCGGCCG GGTCGAAGGTGAGCGCCGGGCGCCAGAGTTCGGGGAAGACCTCCTGGTCCACGAGGGCGCGGGCCACCTC GGGCGGGCAGTAGGCGGCGAGGGCCGCCTCGGAGGGCCGCGGCGTGTGGGTCTCGCCGGCCGGGACGCGG CGGAAGCCGCCGTCGGGCGCGGGGTGCTCGGGCATGGGCCCGAGCGGGCGCCGGAGCCGGTCGTCCTCGG AGGAGGAGGAGGAGGAGGACAGCAGCGCGGGAGCGGGGTCCGGAGCGGGCCCGAGTCCGAGGGAGCGGCG CTTGCGCCGGGGCCCCCGGTCCTCTTCGTCGTCGCGGTGGCCGTGGCCGTCCCCGCGGAGGGCCGCGCCG GAGAGCCCCTCGTCCTCCTCGCCGTCCCCGGGGCGGCGGGCCCCGGGCGCGCGGCGCTTCTTCTTGCGCC GCTCGGGCGCTGGGTCCGGGCCGGCGGCGGGGGAGCTGGCGTAGCCGGAGGAGCCGGAGAGGCCGGACTT GGTGCTGGAGCTGGACTTGGTGCTGGAGCTGGACTTGGTGCTGGCGGGGCTGGAGGGCCCGGAGCCGGGG AGGCCGGAGGGGGCGCCCGCCGCCGCCGGCGCCGGCGCTGGGACGACGAGGCCGGGCTGCTCGGGCCAGA GCGGGGGCAGGCCGGGCGCGGGCTCCGCGGGCCCGGGCCGCGCGGCGGCCTCGGCGAGCCGGGCCGCGGC CACGTTGGCCGGGGCGAAGAGGGCCGCGGCGTAGGTCCAGGCGGCCTCGCGGGCGCGGGCCCCGTCCACG CTGTAGCGCACCAGCGGCGCCACGGTGCGGGCGACGAGGGCGACAGAGTCCGCGGCCTGCCGCCGCTCGG CCGGGCCGGCCCCGGGGATCGCGTCGCGGAGCGCGAGCAGCGCGGCCGTCACCTCCTCGAGGCAGGCGGG CCCGAGGGCGGCCGGGGCGCGGGCGGGCGCGGGCAGCCGGAGCGGGCAGGGCAGCAGGCGCTCGAGGACG CCGCGGCAGGCCAGGACGCAGGCGTCCGCCAGCTCGCGGGGCACGCGGCCGGGCTGCGCGGCGGCGAAGG CGGCGCGGACGCGGGCGCAGAGGGCCTCGACGGTCGCCTCCCCGGCGCGGGGGTCCGCGGCGCGGCCCGG GTAGGCCATGTCGGCGTAGGCCCGGCGGAGGCTCTGCAGGATGAAGGTCTTCTGGGTGCGATCGTAGCGG CGGCTCATGGCCACGGCGCTCACCGCGTGCGGCAGGGCCCAGAGCGGGTCCTGGGCGGCCATGGCGTCCC CGATGTGCGGCAGCGGCGGGGTCACGCTGCCGGTGATGAAGGAGCCGTGGCCGTGGGGCGCGTGGACCCG GCGCTGGCAGAACTGGTTGAAGCGCTGGTCGGGGGCCTGCATCCGCGGGTTCTGCAGCCAGGACATGGCC TCGCCGGCGGCCCCGCTGTAGATGAGGCGCACGAGGGCCTCGTGCTGCTTCCTCGAGTCCCCCATCTCCG GGATGAAGACGGGCACGGGCCCGGCCGCGGCGCGGTAGCGGGCCGCGGCCTGGCGGACGTCGTCCTCGTC CCAGAGCCCCTCGCGGGAGTCCCCGGCGCCGCCGTAGCGGACGCGGCCGTCGGCCGGAGGGTCGGAGCCG GGCCAGGGCTCCCCGAGCGGGGTGAGCAGCGGCCCGTCGGTCGGCGGGGGCCCGTCGGCCATGAGCGAGA GGTGGTTGTTGGTGGAGCGGCGCTTCCTGCGCGGGGGCCGGGCGGGCTCCGGGGCCGGGGCCGGGGAGGC CGCGGCGGAGGAGGAGGCGGAGGAGGCCGAGGGCCGCGGGGCCGCGGCGGGCGCCGGCGGAGACGGTGGC GGCCCGGCGCGGGCGAGTGGGGCGCCGGGCCGGACTCCTTCGTCTTCTTCTCCCTCGGAGGAGGACGAGG ACGAGGAGGACGAGGAGGACGAGGAGGACGAGGACGAGGAGGAGGCCGAGCGCCGCGCGGCGGCGGCGGG GGCCCGGGGGGCGGAGGGCGAGCGGGCCGGGGAGAGGTCCGAGTCGCTGCCGCTGCTGCTGGAGCTGCTG AAGCCGCGGCCGCGGCGGAGGGCGCCCTCTCCGGCGCGGCGCCGGCGGGGCTGTCTCTGCGGGGGCGCCC CGCCGTCCCCGGCGAGGCCGAGTCCGTCCTCGTCCTTCTCGGGGCCGCGGGCGACGGTCTCGACGGCGAC GGTGGTGGTGGAGTTGGAGTTGGAGTTGGGGTTGGAGGAGACGGGGCTCCGGGCGCCAAGCGGCCGAGGA TCGAGCCGCCTCGCGGCGGCGGGCTCGTCGAGCAGGGGCTCGCGGTGCTGGTGATGGTGACGACCGCGGT CCCCTCCGGCGGAGGGGGCGCCGCCGCCGCCGGGCGCCGAGACCGGCCCGGCGGCGGGGGAGGCTGGGGA AGCGGGCCCCCGCCGTGCCGGCGCTGCGGCCACCGCTGCTGGCTGTGCTGGTGGCGCCGGGGTCCGAGGC CGCGCCGCCGGCCCGGGCTCACCGACCGGGTCCCCCCTCGCGGGGGACCATCTCCGCGGGGCTGCCGAGG GGCCGGGAGAGCCGGAGGAGGAGGCCGGGGAGGCTGCGGAGGGGGACGAGCGCCCGGGGCCGCCGGGGGC CCCGGCCTCTGCCGCTGCGAGTGCTGCCGGGGTCGGCGGCCGGGGCCCGGAGCCGGCCCGGGACCGGGGC CCGAGGACGAGGTGACCGTGCTCGGAGCCCTGATGGAGAGCCCGACCGGGGGACCCGGCGGCCGGGGACC CGGGCTCGTCCTCCTCCTCGTCTTCGTCGTCTAGCACCACGATCTCGCCCGAGCCCCGGCGGGGCTGCTG CTGCTGCTGGGCCGAAGGAGGACGGGGCGGCCTCGTGGCTCCGGCCGCGGCCGCGAGGACGGCGGCCTCG GCCTCGGCGGCGTCGTCGGAGAAGAGGCCGCCCGGGCCGAAGAGGAGATCCTCGCCGGAGGAGCCGCGGC GCCGGGAGCCCTGGCTGCCGCCGTCGGGGCCGGACGCGATGCCCTCTTCCTCGGCCGCGGCGGCGGCCGC CAGGAGCTGGCTGAAGTTGCCCTCGGTCTCGATGAAGTCAAAGAGATCGTCGGCCATGGTCTCGATCGGG GTCTTTCTGCCTGAGCGAGGCCGGGCGCCGAGCGCGGAGAGCGGGCGGCGGAGAAGAAGGAGGAAGGCGG CCGGAGGAGGAGAAGAAGAAGACTCTTCTCTGGCGGGCCGAGAGCCTCGGTGGGTCGGGCGTCCGTCGAG GGCTGATAGCCGCCGGAGAGCCGGAGTCTTCAGAGTCCGCGCCGGAGCGGAGACGGTCGGATCCCCTCGG GTTGGCAGAGAACGATGCTGTCCGTACCTGCACCGCAGTGAAGTGCTACGATGGAGACCGCGCTTATAA >gi|51557548|ref|YP_068382.1| transcriptional regulator ICP4 [Suid herpesvirus 1] MADDLFDFIETEGNFSQLLAAAAAAEEEGIASGPDGGSQGSRRRGSSGEDLLFGPGGLFSDDAAEAEAAV LAAAAGATRPPRPPSAQQQQQPRRGSGEIVVLDDEDEEEDEPGSPAAGSPGRALHQGSEHGHLVLGPRSR AGSGPRPPTPAALAAAEAGAPGGPGRSSPSAASPASSSGSPGPSAAPRRWSPARGDPVGEPGPAARPRTP APPAQPAAVAAAPARRGPASPASPAAGPVSAPGGGGAPSAGGDRGRHHHQHREPLLDEPAAARRLDPRPL GARSPVSSNPNSNSNSTTTVAVETVARGPEKDEDGLGLAGDGGAPPQRQPRRRRAGEGALRRGRGFSSSS SSGSDSDLSPARSPSAPRAPAAAARRSASSSSSSSSSSSSSSSSSSSEGEEDEGVRPGAPLARAGPPPSP PAPAAAPRPSASSASSSAAASPAPAPEPARPPRRKRRSTNNHLSLMADGPPPTDGPLLTPLGEPWPGSDP PADGRVRYGGAGDSREGLWDEDDVRQAAARYRAAAGPVPVFIPEMGDSRKQHEALVRLIYSGAAGEAMSW LQNPRMQAPDQRFNQFCQRRVHAPHGHGSFITGSVTPPLPHIGDAMAAQDPLWALPHAVSAVAMSRRYDR TQKTFILQSLRRAYADMAYPGRAADPRAGEATVEALCARVRAAFAAAQPGRVPRELADACVLACRGVLER LLPCPLRLPAPARAPAALGPACLEEVTAALLALRDAIPGAGPAERRQAADSVALVARTVAPLVRYSVDGA RAREAAWTYAAALFAPANVAAARLAEAAARPGPAEPAPGLPPLWPEQPGLVVPAPAPAAAGAPSGLPGSG PSSPASTKSSSSTKSSSSTKSGLSGSSGYASSPAAGPDPAPERRKKKRRAPGARRPGDGEEDEGLSGAAL RGDGHGHRDDEEDRGPRRKRRSLGLGPAPDPAPALLSSSSSSSEDDRLRRPLGPMPEHPAPDGGFRRVPA GETHTPRPSEAALAAYCPPEVARALVDQEVFPELWRPALTFDPAALAHIAARRGAPLRRRAAWMRQIADP EDVRVVVLYDPLPHEELCAEPAEGAPRPAWDPRRGGLSALLAAFAHRLCTPDSHAWAGNWTGRPDIGRLN AQGVLLLSARDLGFAGAVEYLCSRLGAARRRLIVLDTIEDWPADGPAVGDYHVYVRVRLDPAAQCAVRWP GCRELRAAVLDSSSIVGPACFARVEASFARLHPGAEPLRLCRQDNVRYTVSTRAGPRTPVPLPPRAYRQR VLPTVDGCKDMARQRSALGLGDPDFDAGAAFGHRAANRWGLGAPLRPVFVSCGRRGLAELRGPEGLPAEL RAFCAAALLEPDAEAAPLVLTPGAVAAAGAPPAVLWDFAPFETSVRAAAGGAVETHRPAGASGAGAGPGE DGDSVEIVGVRGGDGRPRGPLGPIKVEAISDDEEAEDAGNPYLLLR Virmugen A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3 [Ref1980:Peeters et al., 1994]. IE180 Suid alphaherpesvirus 1 VO_0011242 2952540 51557548 SuHV1_gp63 BK001744 YP_068382 10345 102695 107803 - transcriptional regulator ICP4 8.04 141692.15 1446 transcriptional regulator ICP4; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA; transcriptional regulator ICP4 ( infected-cell polypeptide 4) is a sequence-specific transcriptional activator that is required for efficient transcription of early and late viral genes; ICP4 is essential for productive infection >NC_006151.1:102695-107803 Suid herpesvirus 1, complete genome CAGAAAATACAGCACAAACTTTATTTTCTCACTCTGAAAACAAACTCTTTTCTCACCCGATGGGAGAAGG AGGAGAAGGGGACCGGGGGACCGCGGGAGGAGGAGAAGGGGACCGGGACGATCCTCCGCCGCCGAGCCCT CCGCCGCGGCCGCCGCCGCCGCTTCCACCACCGCCGCCACCTCCGCCGCCGCCGCAGCCACCTCCGGCCG GGGGATCCGCGCGGAGGAGAAGGAGAGGAGGAGGGCCACCGGGCCGGGGAGGCAGGCGCCGGGGAGGCAA GCGCCGCCGGGCCGAGGGGACCGAGGCCGCCGCCGCGGACGCAGAGGAGGAGGAGGACGGGGACGGGGAC GAGGACGAGGACGAGGACCGGGCCGAGGGCGAGGGGAGAGAAGACGGAGGAGAAGGGCCTCGAGGAGCCG GTGGAGGGGCCGGAGAGTCAGAGTCAGAGTCCGGCCGGGCCGAGGGGGCGCCCCGCTCAGCGGAGCAGCA GGTAGGGGTTGCCGGCGTCCTCGGCCTCCTCGTCGTCCGAGATGGCCTCCACCTTGATGGGCCCGAGCGG GCCGCGGGGCCGGCCGTCGCCGCCGCGGACGCCGACGATCTCCACAGAGTCCCCGTCCTCGCCGGGGCCG GCCCCGGCGCCCGAGGCCCCCGCGGGCCGGTGGGTCTCCACGGCGCCCCCGGCGGCGGCGCGGACGCTGG TCTCGAAGGGGGCAAAGTCCCAGAGCACGGCCGGCGGGGCGCCCGCGGCGGCGACGGCGCCCGGGGTCAG CACCAGCGGGGCGGCCTCGGCGTCGGGCTCCAGCAGCGCCGCGGCGCAGAAGGCGCGCAACTCGGCCGGC AGGCCCTCGGGGCCGCGGAGCTCGGCGAGGCCCCGGCGGCCGCAGGAGACGAAGACGGGCCGCAGCGGGG CGCCGAGCCCCCAGCGGTTGGCCGCGCGGTGCCCGAAGGCGGCGCCCGCGTCAAAGTCCGGGTCCCCGAG CCCGAGCGCGGAGCGCTGGCGGGCCATGTCCTTGCAGCCGTCCACGGTGGGGAGCACGCGCTGGCGGTAG GCGCGCGGCGGCAGCGGGACCGGGGTCCGGGGCCCGGCGCGGGTGCTCACCGTGTAGCGCACGTTGTCCT GGCGGCAGAGGCGCAGCGGCTCGGCCCCGGGGTGCAGGCGGGCGAAGGAGGCCTCCACGCGGGCGAAGCA GGCCGGGCCCACGATGGAGCTAGAGTCCAGCACGGCCGCGCGGAGCTCGCGGCACCCGGGCCAGCGCACG GCGCACTGGGCGGCCGGGTCCAGGCGGACGCGGACGTAGACGTGGTAGTCCCCCACGGCCGGGCCGTCCG CGGGCCAGTCCTCGATGGTGTCCAGCACGATGAGCCGGCGCCGCGCCGCGCCGAGCCGCGAGCAGAGGTA CTCCACGGCGCCGGCGAAGCCGAGGTCCCGCGCCGAGAGCAGCAGCACCCCCTGGGCGTTGAGGCGGCCG ATGTCGGGGCGCCCGGTCCAGTTCCCGGCCCAGGCGTGCGAGTCCGGCGTGCAGAGGCGGTGGGCGAAGG CGGCGAGCAGCGCCGAGAGGCCGCCGCGGCGCGGGTCCCAGGCCGGGCGCGGGGCGCCCTCGGCGGGCTC GGCGCAGAGCTCCTCGTGGGGCAGCGGGTCGTAGAGCACCACCACGCGCACGTCCTCGGGGTCGGCTATC TGCCGCATCCAGGCGGCGCGGCGGCGGAGCGGGGCGCCGCGGCGCGCGGCGATGTGCGCCAGGGCGGCCG GGTCGAAGGTGAGCGCCGGGCGCCAGAGTTCGGGGAAGACCTCCTGGTCCACGAGGGCGCGGGCCACCTC GGGCGGGCAGTAGGCGGCGAGGGCCGCCTCGGAGGGCCGCGGCGTGTGGGTCTCGCCGGCCGGGACGCGG CGGAAGCCGCCGTCGGGCGCGGGGTGCTCGGGCATGGGCCCGAGCGGGCGCCGGAGCCGGTCGTCCTCGG AGGAGGAGGAGGAGGAGGACAGCAGCGCGGGAGCGGGGTCCGGAGCGGGCCCGAGTCCGAGGGAGCGGCG CTTGCGCCGGGGCCCCCGGTCCTCTTCGTCGTCGCGGTGGCCGTGGCCGTCCCCGCGGAGGGCCGCGCCG GAGAGCCCCTCGTCCTCCTCGCCGTCCCCGGGGCGGCGGGCCCCGGGCGCGCGGCGCTTCTTCTTGCGCC GCTCGGGCGCTGGGTCCGGGCCGGCGGCGGGGGAGCTGGCGTAGCCGGAGGAGCCGGAGAGGCCGGACTT GGTGCTGGAGCTGGACTTGGTGCTGGAGCTGGACTTGGTGCTGGCGGGGCTGGAGGGCCCGGAGCCGGGG AGGCCGGAGGGGGCGCCCGCCGCCGCCGGCGCCGGCGCTGGGACGACGAGGCCGGGCTGCTCGGGCCAGA GCGGGGGCAGGCCGGGCGCGGGCTCCGCGGGCCCGGGCCGCGCGGCGGCCTCGGCGAGCCGGGCCGCGGC CACGTTGGCCGGGGCGAAGAGGGCCGCGGCGTAGGTCCAGGCGGCCTCGCGGGCGCGGGCCCCGTCCACG CTGTAGCGCACCAGCGGCGCCACGGTGCGGGCGACGAGGGCGACAGAGTCCGCGGCCTGCCGCCGCTCGG CCGGGCCGGCCCCGGGGATCGCGTCGCGGAGCGCGAGCAGCGCGGCCGTCACCTCCTCGAGGCAGGCGGG CCCGAGGGCGGCCGGGGCGCGGGCGGGCGCGGGCAGCCGGAGCGGGCAGGGCAGCAGGCGCTCGAGGACG CCGCGGCAGGCCAGGACGCAGGCGTCCGCCAGCTCGCGGGGCACGCGGCCGGGCTGCGCGGCGGCGAAGG CGGCGCGGACGCGGGCGCAGAGGGCCTCGACGGTCGCCTCCCCGGCGCGGGGGTCCGCGGCGCGGCCCGG GTAGGCCATGTCGGCGTAGGCCCGGCGGAGGCTCTGCAGGATGAAGGTCTTCTGGGTGCGATCGTAGCGG CGGCTCATGGCCACGGCGCTCACCGCGTGCGGCAGGGCCCAGAGCGGGTCCTGGGCGGCCATGGCGTCCC CGATGTGCGGCAGCGGCGGGGTCACGCTGCCGGTGATGAAGGAGCCGTGGCCGTGGGGCGCGTGGACCCG GCGCTGGCAGAACTGGTTGAAGCGCTGGTCGGGGGCCTGCATCCGCGGGTTCTGCAGCCAGGACATGGCC TCGCCGGCGGCCCCGCTGTAGATGAGGCGCACGAGGGCCTCGTGCTGCTTCCTCGAGTCCCCCATCTCCG GGATGAAGACGGGCACGGGCCCGGCCGCGGCGCGGTAGCGGGCCGCGGCCTGGCGGACGTCGTCCTCGTC CCAGAGCCCCTCGCGGGAGTCCCCGGCGCCGCCGTAGCGGACGCGGCCGTCGGCCGGAGGGTCGGAGCCG GGCCAGGGCTCCCCGAGCGGGGTGAGCAGCGGCCCGTCGGTCGGCGGGGGCCCGTCGGCCATGAGCGAGA GGTGGTTGTTGGTGGAGCGGCGCTTCCTGCGCGGGGGCCGGGCGGGCTCCGGGGCCGGGGCCGGGGAGGC CGCGGCGGAGGAGGAGGCGGAGGAGGCCGAGGGCCGCGGGGCCGCGGCGGGCGCCGGCGGAGACGGTGGC GGCCCGGCGCGGGCGAGTGGGGCGCCGGGCCGGACTCCTTCGTCTTCTTCTCCCTCGGAGGAGGACGAGG ACGAGGAGGACGAGGAGGACGAGGAGGACGAGGACGAGGAGGAGGCCGAGCGCCGCGCGGCGGCGGCGGG GGCCCGGGGGGCGGAGGGCGAGCGGGCCGGGGAGAGGTCCGAGTCGCTGCCGCTGCTGCTGGAGCTGCTG AAGCCGCGGCCGCGGCGGAGGGCGCCCTCTCCGGCGCGGCGCCGGCGGGGCTGTCTCTGCGGGGGCGCCC CGCCGTCCCCGGCGAGGCCGAGTCCGTCCTCGTCCTTCTCGGGGCCGCGGGCGACGGTCTCGACGGCGAC GGTGGTGGTGGAGTTGGAGTTGGAGTTGGGGTTGGAGGAGACGGGGCTCCGGGCGCCAAGCGGCCGAGGA TCGAGCCGCCTCGCGGCGGCGGGCTCGTCGAGCAGGGGCTCGCGGTGCTGGTGATGGTGACGACCGCGGT CCCCTCCGGCGGAGGGGGCGCCGCCGCCGCCGGGCGCCGAGACCGGCCCGGCGGCGGGGGAGGCTGGGGA AGCGGGCCCCCGCCGTGCCGGCGCTGCGGCCACCGCTGCTGGCTGTGCTGGTGGCGCCGGGGTCCGAGGC CGCGCCGCCGGCCCGGGCTCACCGACCGGGTCCCCCCTCGCGGGGGACCATCTCCGCGGGGCTGCCGAGG GGCCGGGAGAGCCGGAGGAGGAGGCCGGGGAGGCTGCGGAGGGGGACGAGCGCCCGGGGCCGCCGGGGGC CCCGGCCTCTGCCGCTGCGAGTGCTGCCGGGGTCGGCGGCCGGGGCCCGGAGCCGGCCCGGGACCGGGGC CCGAGGACGAGGTGACCGTGCTCGGAGCCCTGATGGAGAGCCCGACCGGGGGACCCGGCGGCCGGGGACC CGGGCTCGTCCTCCTCCTCGTCTTCGTCGTCTAGCACCACGATCTCGCCCGAGCCCCGGCGGGGCTGCTG CTGCTGCTGGGCCGAAGGAGGACGGGGCGGCCTCGTGGCTCCGGCCGCGGCCGCGAGGACGGCGGCCTCG GCCTCGGCGGCGTCGTCGGAGAAGAGGCCGCCCGGGCCGAAGAGGAGATCCTCGCCGGAGGAGCCGCGGC GCCGGGAGCCCTGGCTGCCGCCGTCGGGGCCGGACGCGATGCCCTCTTCCTCGGCCGCGGCGGCGGCCGC CAGGAGCTGGCTGAAGTTGCCCTCGGTCTCGATGAAGTCAAAGAGATCGTCGGCCATGGTCTCGATCGGG GTCTTTCTGCCTGAGCGAGGCCGGGCGCCGAGCGCGGAGAGCGGGCGGCGGAGAAGAAGGAGGAAGGCGG CCGGAGGAGGAGAAGAAGAAGACTCTTCTCTGGCGGGCCGAGAGCCTCGGTGGGTCGGGCGTCCGTCGAG GGCTGATAGCCGCCGGAGAGCCGGAGTCTTCAGAGTCCGCGCCGGAGCGGAGACGGTCGGATCCCCTCGG GTTGGCAGAGAACGATGCTGTCCGTACCTGCACCGCAGTGAAGTGCTACGATGGAGACCGCGCTTATAA >YP_068382.1 transcriptional regulator ICP4 [Suid alphaherpesvirus 1] MADDLFDFIETEGNFSQLLAAAAAAEEEGIASGPDGGSQGSRRRGSSGEDLLFGPGGLFSDDAAEAEAAV LAAAAGATRPPRPPSAQQQQQPRRGSGEIVVLDDEDEEEDEPGSPAAGSPGRALHQGSEHGHLVLGPRSR AGSGPRPPTPAALAAAEAGAPGGPGRSSPSAASPASSSGSPGPSAAPRRWSPARGDPVGEPGPAARPRTP APPAQPAAVAAAPARRGPASPASPAAGPVSAPGGGGAPSAGGDRGRHHHQHREPLLDEPAAARRLDPRPL GARSPVSSNPNSNSNSTTTVAVETVARGPEKDEDGLGLAGDGGAPPQRQPRRRRAGEGALRRGRGFSSSS SSGSDSDLSPARSPSAPRAPAAAARRSASSSSSSSSSSSSSSSSSSSEGEEDEGVRPGAPLARAGPPPSP PAPAAAPRPSASSASSSAAASPAPAPEPARPPRRKRRSTNNHLSLMADGPPPTDGPLLTPLGEPWPGSDP PADGRVRYGGAGDSREGLWDEDDVRQAAARYRAAAGPVPVFIPEMGDSRKQHEALVRLIYSGAAGEAMSW LQNPRMQAPDQRFNQFCQRRVHAPHGHGSFITGSVTPPLPHIGDAMAAQDPLWALPHAVSAVAMSRRYDR TQKTFILQSLRRAYADMAYPGRAADPRAGEATVEALCARVRAAFAAAQPGRVPRELADACVLACRGVLER LLPCPLRLPAPARAPAALGPACLEEVTAALLALRDAIPGAGPAERRQAADSVALVARTVAPLVRYSVDGA RAREAAWTYAAALFAPANVAAARLAEAAARPGPAEPAPGLPPLWPEQPGLVVPAPAPAAAGAPSGLPGSG PSSPASTKSSSSTKSSSSTKSGLSGSSGYASSPAAGPDPAPERRKKKRRAPGARRPGDGEEDEGLSGAAL RGDGHGHRDDEEDRGPRRKRRSLGLGPAPDPAPALLSSSSSSSEDDRLRRPLGPMPEHPAPDGGFRRVPA GETHTPRPSEAALAAYCPPEVARALVDQEVFPELWRPALTFDPAALAHIAARRGAPLRRRAAWMRQIADP EDVRVVVLYDPLPHEELCAEPAEGAPRPAWDPRRGGLSALLAAFAHRLCTPDSHAWAGNWTGRPDIGRLN AQGVLLLSARDLGFAGAVEYLCSRLGAARRRLIVLDTIEDWPADGPAVGDYHVYVRVRLDPAAQCAVRWP GCRELRAAVLDSSSIVGPACFARVEASFARLHPGAEPLRLCRQDNVRYTVSTRAGPRTPVPLPPRAYRQR VLPTVDGCKDMARQRSALGLGDPDFDAGAAFGHRAANRWGLGAPLRPVFVSCGRRGLAELRGPEGLPAEL RAFCAAALLEPDAEAAPLVLTPGAVAAAGAPPAVLWDFAPFETSVRAAAGGAVETHRPAGASGAGAGPGE DGDSVEIVGVRGGDGRPRGPLGPIKVEAISDDEEAEDAGNPYLLLR Protective antigen To examine the response by IE180 more closely, a vaccine trial in mice with a vector DNA construct that contains the gene encoding for IE180, designated pcDNAIE180 was conducted. Seven months after immunization with pcDNAIE180, an overall 25% of BALB/c, C3H/HeJ, and C57BL/6 mice receiving a lethal PrV challenge were protected [Ref1246:Chang et al., 1998]. Ifng (Interferon gamma) Mouse 15978 33468859 NM_008337 NP_032363.1 MGI:107656; UniProt:P01580 10090 ? >gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA AGTATACCTTTGCAACC >gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus] MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ LLPESSLRKRKRSRC IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria. Vaximmutor The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes [Ref2101:Wang et al., 2009]. Il2 Mus musculus 16183 7110653 DN-144H19.3 AF195954 NP_032392 10090 3 37120712 37125953 - interleukin 2 4.63 18506.61 169 Also known as Il-2 >gi|372099107:37120712-37125953 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J ATTTTTTTTTAGAGGAGAGCTTTATTTCTTGAAAACACTGATTAACATAGAGTTCACAGGAATAACTGAG AAGTTATTTTAGCGCTTACTTTGTGCTGTCCTAAAAATGACAGACATCTGAGCTTATTTATATTTGAATC ATCTAAATACTTTTATTAATGAGTCTACCTACACATGATATTTAACAATTCAATATAATAAATAATTTCA GATAAATAGTTTAAAACATTTTTGAGCCCTTGGGGCTTACAAAAAGAATCTTTAAAGATCCATATTTATC ATCTGAAGACTAGTAGTTACAAAAGATAGTAAACAATACATCCAAAAATAAATTAAAGTTAAATATTTAA ATAAATAGAGAGCCTTATGTGTTGTAAGCAGGAGGTACATAGTTATTGAGGGCTTGTTGAGATGATGCTT TGACAGAAGGCTATCCATCTCCTCAGAAAGTCCACCACAGTTGCTGACTCATCATCGAATTGGCACTCAA ATGTGTTGTCAGAGCCCTAAAAAAGAATATAAAATTGTAGGCTAAGGTAGCTTACTTTGCATATAATTAT TCTTCACGGAAGCTTTTAGGCATTTATTTTAACACTGGTTAAATATATTGAACATTCACATTTCTGAAAT GATCACAATTATTGGGTTATGTTTTATTATGATATCAAATGGTAAAGCATAAAAAATAAAGCTCTCCAGA GTTGATTACCAACGAGCATTTGATGGGAACACTGAACACTTCTGTAGAATTCAGTTGCTTGACCACTTTT TCTCTGGTAAGTGTACACAGCTATGCATCAATTTAGGCTTCAGGAATGGAGAAATGATACTTGTTATATG TTCTTTGCTAAATCTTAAGAGTCTATTATTCAATTCTTTCCCCCCCAAGTCAGAATGGGAACAACCCAGA GTAGGTTAGGACAAGCATCTATTGGGGGAAATTTGGAGAATTTTGTTATAGATATACCTACCCTGATACC AGTGTAGATGAATCACAAAGTTTGTACATGTATAAATATTATAAATTTGTTCTGTGGATTAGCTTTTTGA AAGCTAACCCTCTTTGCTAAAGGAGATATTTTAATTCTGTTTTTAGGTGACAAGCTGAGAAGGAAATATT TTGACAAATTTATGGGATGGCTTTTCCAAATCTGACTAATTCCTTGTAAGTCAAATGAGGCAGATTATTC CTTTTAAATAAATACTCCTTTTCAAATAAGCTGCTGTGGTCTTATATACCCTCTTTACATAGCTACTTCA ATATTCTAATGTCTTGAATTTTTCATTTTTAAAAATATGTGGCCCTTGAAACATTTTTCTAGTTCTCATG TAGCTCTAAAGTTTGTACCATTCATTAGGGGTGAACTTTCTGATGTTGGCCATAGATTTTAGAGCATCCA TCTTTGCATACGTAAGTACTCGATTTTAGAGCATCCATCTTAGCATACGTAAGTACTCACACCTTTCAAC GTCTAGATGATGTGTATTTCAGCCTGCTTTAAAAACCTCAAATGGAAGCTGGGCAGTGGTGGTGCAGGCC TTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAGT GAGTTCCAGGACAGCCAGGGCTACACAGAGAAATCCTGTCTCAAAAAAACAAACAAACAAACAAACAAGA AACAAACAAACAAAAAAAACAAAAACAAACAAAACAAAACCTCAAATGGAAACAGTGCACTGAAATGTGA CTTTGGTTTGGAAAGGACTAGCCCACACCCTCTTGGAGGCTTGCTGCTACTGTCTCACCAGAGTCCATGA TTCTTGTGCATTTAAAAACAAAGCTCTGCAGTGGGCTCTCCCCGTCCTGCTCTGTCCATTTTAATGGCTG CCATTTTTGGAGAGAAATGTCTGTTTTTCTACCAATACCAGCACAACTTCTCTGGAAAAACTTTTCAGAT AATTTTTTCTGATCTGATGAATGTAACACCAGCAAGAGTTGCTTGTTTCTTGTGGAATTCTACTCCGTGC TTTCTCTCACATCCAGTTCTATGCTGGTGTGGAGGGAGCAGAGTGTTCATGTTCCCAGTTTCCTTGCAGG TGATGGTAGGTGGAAATTCTAGCATCATCCTACAGTGGAAGGATTCACTTGCACAGTGACTTTAAACTTT GGCTGACTAAATGCACAGAACCCATCAAAGACCAGAAATGGCAAGCCACTTAAAAATGCATTTCTTCTCT ATTTTATTTCCAGATTAGCAAATAAAGCAACACCTTACCTTTAGTTTTACAACAGTTACTCTGATATTGC TGATGAAATTCTCAGCATCTTCCAATTGAAAGCTTTTGCTTTGAGTCAAATCCAGAACATGCCGCAGAGG TCCAAGTTCATCTTCTAGGCACTGAAGATCTTTCAATTCTGTGGCCTAGAGGAGTAATAAGCTTAACCAT CAGCTCAGCTCACCACATACTGAAGAGCCAGAAAGTTAGTCTGCAGTCTCTCTAATCAAGAGAAGGCAGC ACATAGCTTTTACCACTCCCTGTCCTCTGTAAAGGGGGACTGAGGTAATCGATGCCATAAATCTAGAAGA GCAAGAGCTCACAACCATAAGGGTCACCTTGACTGTTAGGCCACTCTAGTGAGCTCTTCTGGCTTCATTA GACTTTGTAAAAAGTCTGTGTTTCTCTACCAATGCATAGCACAAGTTCAGACTATTGTTCCAATCTACAA AGAAATCTGCAAGGTTCACATTCTAATATCTAATCGCAGAGTTGAGAATCACAGAAGGGTAAGGGACAGG AATCCTTGGATGCCAACTGTCATAGGCCTAAATCTTACAGATTAGGTTATCATGGCCCTGACTGAGGGGT GTCAAGATAGCCAGGAAGACACATGTAATATTTTTTAAATTTATACTTCTCTGCAATTACTAAAGATGAG TTTTTTAAAAACCCATATGTCAAGCTAGGAAGATGGCTTTTAAGGTAAAGGTACCTGCCACCAAACTTGA TGATTTGAGTTCAATTGCAGTGACCCACCCACATTGTGGAAAGAATGGCCCAACTTTCATATTTCGTCTT CTGACCTCCACAGTTACACTGTGATACACATGCACCTCCACACATACATACATACATACATACATACATA CATACATACATACATACATACATACATAAAATGTAAAATCTATTTGTCCCAATGAAAAAAGTCATAACAT TTTGGCAGAACACTTGGGAGAATTTTTCTGATCCATGTATGAAATAATGTTTAAATACATCATGCATACT TACATACATATACAGGGAAAAAGGATATTGTCTAGCTCTATAGTACACTATGATTTCCATAAAGTCAGCT GCTTTAAGTCTACAGTGAACTGTGTTATCTCCATTTTACCAAGTCTCACAATCAGTGTCTTTCCCACAAC CACATGAACGGGGAGCAAGGGTGGCCCGGTCGGTCGGTCGCTCCTTTCATTAACCACAGCCTTTGAATTA CATGCTTCTATTGTTTTTAAAATCTTACATACCGAATGCAGGTTAAATGAAAACATCAGCAGAATTTACC ACATTACTCTTGTTTTCAATAATTATTTTAAAACTTAGATTTCTAGGAATTTCACCACTCTCTAAATTAA CATGATCTCTGTTGTTTCTCTAACAATCCTTAGAGGAAGAGGTTTGACAAGATAACACGTAGTTCCTGAT TGGTCTGCTATTGACCTTCCAACTTGTTATGGTGTGTCTTGGGTATTCAGTGTGGAGCTCCTTCCCTCAC AGAACTCTCCAGTTTGTTACTGTGGGAGCTGAACATTATGTGACTGTAATTAAGCTGGAAGAGCAACTGG GGCCTTTCTTTTTCATCTCCTGTAGAACAGCTAGAGGCAAAGTTCCCCTGACTCAATAGGAATGGGTCAA CAGCTGCCTCTTTGTCCCCTTAGATCCCATTTTGCTCTAGGCTTGGATTTACTTGGGACAAGCTCTTTCT AGGACCAAAGTTATCCATTCTCTTTTGACTTTCGGGACTAGAGCAAATTTCTACCCTTGCTGGAGTTCTA AGAGCTTGTGTAAGCTGTTTTGTATCACACAACATTCTGCCTCCAAAGGAGACCAAAAAACCTTTCAATA TTGAGAGATAGTATCATGTAGTAATATTACAGCTCTCTAGTTCCACTAGTTAAAAGAGACTGTATAAATC CAAAATTGTTTTATACATCTCGGACTTCTTCTCTAGCACTAATAGTGTGTTTATGTGCTGTTGGCCAGAC ACTGTTCTGAAACCTGACAAGTGATAAGCATAGCAATGATCATTTATGTAAGTGGGTGAATGAGCATAGA CAACTTCCTGAGGCCATGAGAGCTAGGCCCTAGCAGGGCTGGACTCCACTGCAGATCATTGGCCCTAGAA TCTTAACATTGGTTATGCTGCTCCTCAAAAATGCAGTCATAGGAATCATTCTTAAAACAGTAAAGTGTGT GTAAAATGAGACCCTCTCAAGTCAATTTTTACATTTAAGAAGCTGAAATAATGCACCTCTCTCAAATATC TGTAGGACAAGCATAAAACAGAAATCAACAGTCTTTAAATTATCCCAGCATCAAAATGCAATCATCTTGC ATTTTCTTCTCATTCCCTTTCCCAACACATAAATACACAGGAAAAATGTAAAGAAAACCATTTAAAAGAA GTACCATTGTCAAGATTTTTTTACAGAGAGATATCAGAGAAACTTATTTTCTTCAGATGAGGTACTATTC ATCTGGTCACATGTTATTTACACGTTATACACATGTATGTTACTTTGAATTCATTAGAGCACCAGTTAAA CACAGAAACTCACTCACCTGCTTGGGCAAGTAAAATTTGAAGGTGAGCATCCTGGGGAGTTTCAGGTTCC TGTAATTCTGAGAAAGCGTAACACATTATTATTAAAGGTTATTAAACACAGCCTTTGGCAAGAAAGCTAA AGGTATTGCCTATAGATGGGATGGCTGTGCACTTACCTCCATCCTGCTCAGGAGCTCCTGTAGGTCCATC AACAGCTGCTCCAGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTGCTTCCGCTGTAGAGC TTGAAGTGGAGCTTGAAGTGGGTGCGCTGTTGACAAGGAGCACAAGTGTCAATGTGACACAGGATGCGAG CTGCATGCTGTACATGCCTGCAGGACTTGAGGTCACTGTGAGGAGTGATTAGCAAGGGTGAT >gi|7110653|ref|NP_032392.1| interleukin-2 precursor [Mus musculus] MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKL PRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFEC QFDDESATVVDFLRRWIAFCQSIISTSPQ Vaximmutor Il4 (interleukin 4) Mus musculus 16189 10946584 RP23-188H3.4 NM_021283.1 NM_021283.1 10090 ? IL-4, Interleukin 4 >gi|10946583|ref|NM_021283.1| Mus musculus interleukin 4 (Il4), mRNA GGATCCCCGGGCAGAGCTGGGGGGGGATTTGTTAGCATCTCTTGATAAACTTAATTGTCTCTCGTCACTG ACGGCACAGAGCTATTGATGGGTCTCAACCCCCAGCTAGTTGTCATCCTGCTCTTCTTTCTCGAATGTAC CAGGAGCCATATCCACGGATGCGACAAAAATCACTTGAGAGAGATCATCGGCATTTTGAACGAGGTCACA GGAGAAGGGACGCCATGCACGGAGATGGATGTGCCAAACGTCCTCACAGCAACGAAGAACACCACAGAGA GTGAGCTCGTCTGTAGGGCTTCCAAGGTGCTTCGCATATTTTATTTAAAACATGGGAAAACTCCATGCTT GAAGAAGAACTCTAGTGTTCTCATGGAGCTGCAGAGACTCTTTCGGGCTTTTCGATGCCTGGATTCATCG ATAAGCTGCACCATGAATGAGTCCAAGTCCACATCACTGAAAGACTTCCTGGAAAGCCTAAAGAGCATCA TGCAAATGGATTACTCGTAGTACTGAGCCACCATGCTTTAACTTATGAATTTTTAATGGTTTTATTTTAA TATTTATATATTTATAATTCATAAAATAAAATATTTGTATAATGT >gi|10946584|ref|NP_067258.1| interleukin 4 [Mus musculus] MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCR ASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS Vaximmutor IL-4 plays an important role in Th2 immune response. UL23 Suid herpesvirus 1 2952559 51557518 SuHV1_gp35 BK001744 YP_068352 10345 59511 60589 + thymidine kinase 7.14 32400.33 320 2.7.1.21 >gi|51557483:59511-60589 Suid herpesvirus 1, complete genome GATGCGCATCCTCCGGATCTACCTCGACGGCGCCTACGGCACCGGCAAGAGCACCACTGCCCGGGTGATG GCGCTCGGCGGGGCGCTGTACGTGCCCGAGCCGATGGCGTACTGGCGCACTCTGTTCGACACGGACACGG TGGCCGGTATTTACGATGCGCAGACCCGGAAGCAGAACGGCAGCCTGAGCGAGGAGGACGCGGCCCTCGT CACGGCGCAGCACCAGGCCGCCTTCGCGACGCCGTACCTGCTGCTGCACACGCGCCTGGTCCCGCTCTTC GGGCCCGCGGTCGAGGGCCCGCCCGAGATGACGGTCGTCTTTGACCGCCACCCGGTGGCCGCGACGGTGT GCTTCCCGCTGGCGCGCTTCATCGTCGGGGACATCAGCGCGGCGGCCTTCGTGGGCCTGGCGGCCACGCT GCCCGGGGAGCCCCCCGGCGGCAACCTGGTGGTGGCCTCGCTGGACCCGGACGAGCACCTGCGGCGCCTG CGCGCCCGCGCGCGCGCCGGGGAGCACGTGGACGCGCGCCTGCTCACGGCCCTGCGCAACGTCTACGCCA TGCTGGTCAACACGTCGCGCTACCTGAGCTCGGGGCGCCGCTGGCGCGACGACTGGGGGCGCGCGCCGCG CTTCGACCAGACCACGCGGGACTGCCTCGCGCTCAACGAGCTCTGCCGCCCGCGCGACGACCCCGAGCTC CAGGACACCCTCTTTGGCGCGTACAAGGCGCCCGAGCTCTGCGACCGGCGCGGGCGCCCGCTCGAGGTGC ACGCGTGGGCGATGGACGCGCTCGTGGCCAAGCTGCTGCCGCTGCGCGTCTCCACCGTCGACCTGGGGCC CTCGCCGCGCGTCTGCGCCGCGGCCGTGGCGGCGCAGACGCGCGGCATGGAGGTGACGGAGTCCGCGTAC GGCGACCACATCCGGCAGTGCGTGTGCGCCTTCACGTCGGAGATGGGGGTGTGACCCTCGCCCCTCCCAC CCGCGCCGCGGCCAGATGGAGACCGCGACGGAGGCAACGACGACGGCGTGGGAGGGGGCTCGGGGCGCGT ATAAAGCTATGTGTATGTCATCCCAATAA >gi|51557518|ref|YP_068352.1| thymidine kinase [Suid herpesvirus 1] MRILRIYLDGAYGTGKSTTARVMALGGALYVPEPMAYWRTLFDTDTVAGIYDAQTRKQNGSLSEEDAALV TAQHQAAFATPYLLLHTRLVPLFGPAVEGPPEMTVVFDRHPVAATVCFPLARFIVGDISAAAFVGLAATL PGEPPGGNLVVASLDPDEHLRRLRARARAGEHVDARLLTALRNVYAMLVNTSRYLSSGRRWRDDWGRAPR FDQTTRDCLALNELCRPRDDPELQDTLFGAYKAPELCDRRGRPLEVHAWAMDALVAKLLPLRVSTVDLGP SPRVCAAAVAAQTRGMEVTESAYGDHIRQCVCAFTSEMGV Virmugen A UL23 mutant, in combination with mutations in glycoproteins G and E, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV [Ref1962:Weigel et al., 2003]. UL44 Suid alphaherpesvirus 1 VO_0011239 2952505 51557513 SuHV1_gp30 BK001744 YP_068347 10345 53985 55504 + envelope glycoprotein C 6.98 45878.36 479 envelope glycoprotein C; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; the nonessential glycoprotein gC interacts with cell surface proteoglycans, whereas the essential glycoprotein gD is involved in stable secondary attachment >NC_006151.1:53985-55504 Suid herpesvirus 1, complete genome TTTTAAAACCGCGATGGGGGGACGGGGGGCCATTCGCACGCGCCATGGCCTCGCTCGCGCGTGCGATGCT CGCTCTGCTGGCGCTCTACGCGGCGGCCATCGCCGCGGCGCCGTCGACCACGACGGCGCTCGACACGACG CCCAACGGGGGCGGCGGCGGCAACAGCAGCGAGGGAGAACTCTCGCCCTCTCCGCCCCCGACCCCCGCGC CCGCCTCGCCCGAGGCGGGCGCGGTCTCGACGCCCCCGGTCCCGCCGCCCTCGGTCTCGCGCAGGAAGCC CCCGCGGAACAACAACCGGACGCGCGTCCACGGCGACAAGGCCACCGCGCACGGGCGCAAGCGCATCGTG TGCCGGGAGCGGCTGTTCTCGGCGCGGGTGGGGGACGCGGTCAGCTTCGGGTGCGCCGTCTTCCCGCGCG CCGGGGAGACCTTCGAGGTCCGCTTCTACCGCCGCGGGCGCTTCCGCTCGCCCGACGCCGACCCCGAGTA CTTTGACGAGCCCCCGCGCCCGGAGCTCCCGCGGGAGCGGCTCCTCTTCAGCTCCGCCAACGCCTCCCTC GCCCACGCGGACGCGCTCGCGCCCGTCGTCGTCGAGGGCGAGCGCGCGACCGTCGCCAACGTCTCGGGCG AGGTGTCCGTGCGCGTGGCCGCGGCGGACGCCGAGACCGAGGGCGTCTACACGTGGCGCGTGCTGTCCGC CAACGGCACCGAGGTCCGGAGCGCCAACGTCTCGCTCCTCCTGTACAGCCAGCCCGAGTTCGGCCTGAGC GCGCCGCCCGTCCTCTTCGGTGAGCCCTTCCGGGCGGTGTGCGTCGTCCGCGACTACTACCCGCGGCGCA GCGTGCGCCTGCGCTGGTTCGCGGACGAGCACCCGGTGGACGCCGCCTTCGTGACCAACAGCACCGTGGC CGACGAGCTCGGGCGCCGCACGCGCGTCTCCGTGGTGAACGTGACGCGCGCGGACGTCCCGGGCCTCGCG GCCGCGGACGCCGCGGACGCGCTCGCGCCGAGCCTGCGCTGCGAGGCCGTGTGGTACCGCGACAGCGTGG CCTCGCAGCGCTTCTCCGAGGCCCTGCGCCCCCACGTCTACCACCCGGCGGCGGTCTCGGTGCGCTTCGT CGAGGGCTTCGCCGTCTGCGACGGCCTCTGCGTGCCCCCGGAGGCGCGCCTCGCCTGGTCCGACCACGCC GCCGACACCGTCTACCACCTCGGCGCCTGCGCGGAGCACCCCGGCCTGCTCAACGTGCGGAGCGCCCGCC CGCTGTCGGACCTCGACGGGCCCGTCGACTACACCTGCCGCCTCGAGGGCCTGCCCTCGCAGCTGCCCGT CTTCGAGGACACGCAGCGCTACGACGCCTCCCCCGCGTCCGTGAGCTGGCCCGTCGTGAGCAGCATGATC GTCGTCATCGCCGGCATCGGGATCCTGGCCATCGTGCTGGTCATCATGGCGACGTGCGTCTACTACCGCC GGGCGGGGCCGTGACGCCCCGCGCGTTCCCCCCCCACGTCGAATCAATAA >YP_068347.1 envelope glycoprotein C [Suid alphaherpesvirus 1] MASLARAMLALLALYAAAIAAAPSTTTALDTTPNGGGGGNSSEGELSPSPPPTPAPASPEAGAVSTPPVP PPSVSRRKPPRNNNRTRVHGDKATAHGRKRIVCRERLFSARVGDAVSFGCAVFPRAGETFEVRFYRRGRF RSPDADPEYFDEPPRPELPRERLLFSSANASLAHADALAPVVVEGERATVANVSGEVSVRVAAADAETEG VYTWRVLSANGTEVRSANVSLLLYSQPEFGLSAPPVLFGEPFRAVCVVRDYYPRRSVRLRWFADEHPVDA AFVTNSTVADELGRRTRVSVVNVTRADVPGLAAADAADALAPSLRCEAVWYRDSVASQRFSEALRPHVYH PAAVSVRFVEGFAVCDGLCVPPEARLAWSDHAADTVYHLGACAEHPGLLNVRSARPLSDLDGPVDYTCRL EGLPSQLPVFEDTQRYDASPASVSWPVVSSMIVVIAGIGILAIVLVIMATCVYYRRAGP Protective antigen A trial vaccine containing pseudorabies virus (PRV) glycoprotein gC as the main component showed excellent protection against virulent virus infection in pigs [Ref1253:Katayama et al., 1997]. UL50 Suid herpesvirus 1 2952537 51557490 SuHV1_gp07 BK001744 YP_068324 10345 8442 9457 - deoxyuridine triphosphatase 9.02 26335.82 268 3.6.1.23 >gi|51557483:8442-9457 Suid herpesvirus 1, complete genome CTTTATTGAAAAATGAGAAGAGCGGGCCCCGCGTGTGTGCGCGCGCGGTCGCCACCGTCCGGGTCCGGCG CGGGCCGCCGCGGCCTCACAGGCCCGTGGAGCCGAAGCCGCGGGCCCCGCGCGCGCTGCTCGGGGCGACA AAGTCCCGCGCGAAGAGCCACGCGGGGCGGTGCTGCATCGGGGCGCGCGGGGTGGCGGGGAACGGGGACC GTCCCGTGATCCAGCCCAGCGGCTCGCGCGTCAGCACCAGCTGGGCCACGCGCTGGCCCGACTCCAGGGT CACCGGGTGCGCGCCGCGGTTCTGGATCCGGAAGCGGCACGGGCCGCTCTCCCAGGGCGTGGGGAAGACG ACGATGCCGCGGAGGTTGAGGGACGAGCGCCCGAAGACGTAGGCCCAGTGGCGGCCGTCCGTGCGGTGCA CCGGTAGCGTCACGGTCTCGGCGCCCCCGGGGGGCAGCACCAGCTCGCGCGGGCAGGGGATGTCGTATCC GGCGTCCTCGTCGCGCTTCGGCGCAAAGACCTCGAAGAAGGGCACGTCCGTGGCGATGCCCGGCGCGAGG CGCAGCGGCGTGCAATAAAATTGCGCCCGTGGGCGGCCCGGGGCTACAATCGCCTGCACCTCGCCGCGAA AGCCCGCGTCCACGATCCCGTTGGTGGTGCGACCGCCCCCGCGCTGCGCGACGAGCATCGCGTATCCGGT GGGCAGCGCCACCTTGAGGCCCAGGGGAACCTTATAAAATCCCTCCGGCCCCGGACTCCGGCACACCAGC AGCCGCCCTCCGTCCACGGTCACGGGCTCGCTCGCACACACCAGGATGGTCTCCTCCGCCGGGCTCTCGC TGACGCTCGTCGCCGCGCTCTGCGCGCTGGTGGCCCCCGCGCTCTCTTCCATCGTCTCCACCGAGGGGCC GCTGCCGCTGCTGCGCGAGGAGTCGCGGATCAACTTCTGGAACGCCGCCTGCGCCGCCAGGGGAGTCCCG GTGGATCAGCCCACGGCCGCCGCCGTGACATTTTAT >gi|51557490|ref|YP_068324.1| deoxyuridine triphosphatase [Suid herpesvirus 1] MEESAGATSAQSAATSVSESPAEETILVCASEPVTVDGGRLLVCRSPGPEGFYKVPLGLKVALPTGYAML VAQRGGGRTTNGIVDAGFRGEVQAIVAPGRPRAQFYCTPLRLAPGIATDVPFFEVFAPKRDEDAGYDIPC PRELVLPPGGAETVTLPVHRTDGRHWAYVFGRSSLNLRGIVVFPTPWESGPCRFRIQNRGAHPVTLESGQ RVAQLVLTREPLGWITGRSPFPATPRAPMQHRPAWLFARDFVAPSSARGARGFGSTGL Virmugen A UL50 mutant is attenuated in pseudorabies virus and induces significant protection in pigs from challenge with the highly virulent NIA-3 strain of PrV [Ref1969:Jöns et al., 1997]. US3 Suid herpesvirus 1 2952561 126802155 SuHV1_gp65 BK001744 YP_068384 10345 118238 120955 + serine/threonine protein kinase US3 4.59 34398.44 334 PK family >gi|51557483:118238-120955 Suid herpesvirus 1, complete genome AAATAAAGGAGTCCGGGGAATTTGTTCCTTATACCTTGCCGGGCTCAGCAGGGGGTTGTCGCGCGTCCAC GCCCAGCGCTCGCACGCAGCAACAATGGCCGACGCCGGAATCCCCGACGAGATCCTGTACTCGGACATCA GCGACGACGAGATCATCATCGACGGCGACGGCGACAGCAGCGGGGACGAGGACGACGATGACGGGGGGCT GACGCGGCAGGCCGCGGCGCGCATCGTCACGGACCTGGGCTTCGAGGTGCTGCAGCCCCTGCAGTCGGGC TCGGAGGGCCGCGTCTTCGTGGCCCGCCGGCCGGGCGAGGCGGACACGGTGGTGCTGAAGGTGGGCCAGA AGCCCTCGACGCTGATGGAGGGCATGCTGCTGCAGCGCCTGTCCCACGATAACGTCATGCGCATGAAACA GATGCTCGCCCGGGGCCCGGCGACGTGCCTGGTCCTGCCGCACTTTCGGTGCGATCTGTACAGCTACCTG ACCATGCGGGACGGGCCGCTGGACATGCGCGACGCCGGGTGCGTGATCCGGGCCGTGCTCCGCGGGCTCG CCTACCTGCACGGGATGCGCATCATGCATCGCGACGTCAAGGCGGAGAACATCTTCCTCGAGGACGTGGA CACGGTGTGCCTAGGGGACCTCGGGGCCGCGCGCTGCAACGTGGCGGCGCCCAACTTTTACGGGCTCGCC GGGACCATCGAGACCAACGCCCCCGAGGTGCTCGCGCGCGACCGCTACGACACCAAGGTCGACGTCTGGG GCGCGGGGGTGGTGCTCTTCGAGACGCTGGCCTACCCCAAGACGATCACCGGCGGGGACGAGCCCGCGAT CAACGGGGAGATGCACCTGATCGACCTCATCCGCGCCCTCGGGGTGCACCCCGAGGAGTTCCCGCCCGAC ACGCGCCTCCGGAGCGAGTTCGTCCGGTACGCCGGGACCCACCGCCAGCCGTACACGCAGTACGCGCGCG TGGCTCGCCTCGGGCTGCCCGAGACGGGGGCTTTCCTGATTTACAAGATGTTGACGTTTGATCCCGTCCG CCGCCCTTCCGCTGATGAGATACTCAACTTTGGAATGTGGACCGTATAAAACGGGCCGGCTCCGAGCGGT AGGACACACACACCTTTGCGCATCTCCACAGCTCAACAATGAAGTGGGCAACGTGGATCCTCGCCCTCGG GCTCCTCGTGGTCCGCACCGTCGTGGCCAGAGAGGCCCCTCGGGAGCTCTGCTACGGCCACCCCGTCCAC GACGACCGGCGGCCCGTCGGGCCCGCGACCGACGCCCAGCCCGTGAACCCGCTCGCCCCCGCCAACGCCA CCGGGACGGACTACTCTCGCGGCTGCGAGATGCGCCTCCTGGATCCGCCTCTCGACGTATCGTCCCGCTC CTCGGACCCCGTCAACGTGACCGTCGCCTGGTTCTTTGACGGCGGCCACTGCAAGGTGCCCCTCGTCCAC CGCGAGTACTACGGCTGCCCCGGGGACGCCATGCCCTCCGTCGAGACGTGCACCGGCGGGTACTCGTACA CCCGCACGCGCATCGACACCCTGATGGAGTACGCCCTCGTGAACGCCAGCCTCGTGCTGCAGCCCGGGCT GTACGACGCCGGCCTGTACATCGTCGTGCTCGTCTTTGGCGACGACGCCTACCTCGGCACCGTCTCCCTG TCGGTGGAGGCCAACCTGGACTACCCCTGCGGCATGAAGCACGGGCTCACGATCACCCGCCCCGGGGCCA CCCTCCCACCCATCGCCCCCACGGCCGGCGACCACCAGCGCTGGCGCGGGTGCTTCCCCTCGACCGACGA GGGCGCCTGGGAGAACGTGACCGCCGCCGAGAAGGGCCTGTCCGACGACTACGCCGACTACTACGACGTG CACATCTTCCGCTCGGAGTCTGACGACGAGGTCGTCCACGGCGATGCCCCCGAGGCCCCCGAGGGCGAGG AGGTGACCGAGGAGGAGGCCGAGCTGACCTCCAGCGACCTCGACAACATCGAGATCGAGGTCGTGGGCTC TCCCGCCGCTCCCGCCGAGGGCCCGGCGACGGAGGAGGGGCGCGGGGCCGAGGAGGACGAGGAGCTGACC TCCAGCGACCTCGACAACATCGAGATCGAGGTCGTGGGCTCGCCGCGGCCGCCCGCTTCTTCGCCGCCTC CACCACCCCCGCGCCCCCACCCGCGCGGCCGAGATCACGACCATGACCACGGTCACCACCGTGCGGACGA CCGAGGACCCCAGCGGCATCACCGACTGCCGCCGGAGCCGACCTTCGTCTCGCCCTCTGACATCTTCGTG ACCCCCACCGGCAGCCCCGCCCTGCTCCTGGGCTTCCTGGGCAGCGCGCTCGCCTCGCGCCCCCTGCACC TGACGGCCGGGGAGACGGCCCAGCACGTGCGCGAGGCCCAGCAGAAGAGCCGCCACATCCGCTCCCTCGG CGGCCTCCAGCTCTCGGTCGAGACCGAGACCACCAACACCACCACCACCCAGACGGGCCTGTCGGGCGAC ATCCGCACCTCGATCTACATCTGCGTCGCCCTCGCCGGCCTGGTCGTCGTGGGCATCGTCATCATGTGCC TCCATATGGCGATCATCAGGGCCCGGGCCCGGAACGACGGCTACCGCCACGTGGCCTCCGCCTGACCCGG CCCCGCCCGACTCCCCCGCGATTCCCCCCCTCTCTCACCGGGTGTCCATCTTCAATAA >gi|126802155|ref|YP_068384.2| serine/threonine protein kinase US3 [Suid herpesvirus 1] MADAGIPDEILYSDISDDEIIIDGDGDSSGDEDDDDGGLTRQAAARIVTDLGFEVLQPLQSGSEGRVFVA RRPGEADTVVLKVGQKPSTLMEGMLLQRLSHDNVMRMKQMLARGPATCLVLPHFRCDLYSYLTMRDGPLD MRDAGCVIRAVLRGLAYLHGMRIMHRDVKAENIFLEDVDTVCLGDLGAARCNVAAPNFYGLAGTIETNAP EVLARDRYDTKVDVWGAGVVLFETLAYPKTITGGDEPAINGEMHLIDLIRALGVHPEEFPPDTRLRSEFV RYAGTHRQPYTQYARVARLGLPETGAFLIYKMLTFDPVRRPSADEILNFGMWTV Virmugen Researchers intranasally inoculated pigs, the natural host of this virus, with mutant PRV strains in which the genes encoding the protein kinase (US3) proteins were inactivated. After challenge infection with the virulent PRV strain NIA-3, no virus was excreted by wt PRV- and PK- mutant-immunized animals, indicating complete protective immunity [Ref1256:Kimman et al., 1994]. Brockmeier and Mengeling, 1996 journal Brockmeier SL, Mengeling WL 1996 60 4 315-317 Canadian journal of veterinary research = Revue canadienne de recherche veterinaire Chang et al., 1998 journal Chang SW, Bu J, Rompato G, Garmendia AE 1998 11 1 27-36 Viral immunology Dijkstra et al., 1997 journal Dijkstra JM, Gerdts V, Klupp BG, Mettenleiter TC 1997 78 ( Pt 9) 2147-2151 The Journal of general virology Eo et al., 2006 journal Eo SK, Yoon HA, Aleyas AG, Park SO, Han YW, Chae JS, Lee JH, Song HJ, Cho JG 2006 47 3 451-461 FEMS immunology and medical microbiology Ferrari et al., 2000 journal Ferrari M, Brack A, Romanelli MG, Mettenleiter TC, Corradi A, Dal Mas N, Losio MN, Silini R, Pinoni C, Pratelli A 2000 47 10 753-762 Journal of veterinary medicine. B, Infectious diseases and veterinary public health Fischer et al., 2003 journal Fischer T, Planz O, Stitz L, Rziha HJ 2003 77 17 9312-9323 Journal of virology Fuchs et al., 1990 journal Fuchs W, Rziha HJ, Lukàcs N, Braunschweiger I, Visser N, Lütticken D, Schreurs CS, Thiel HJ, Mettenleiter TC 1990 71 ( Pt 5) 1141-1151 The Journal of general virology Grabowska et al., 2009 journal Grabowska AK, Lipińska AD, Rohde J, Szewczyk B, Bienkowska-Szewczyk K, Rziha HJ 2009 27 27 3584-3591 Vaccine Han et al., 2008 journal Han YW, Aleyas AG, George JA, Kim SJ, Kim HK, Yoon HA, Yoo DJ, Kang SH, Kim K, Eo SK 2008 40 6 583-595 Experimental & molecular medicine Jöns et al., 1997 journal Jöns A, Gerdts V, Lange E, Kaden V, Mettenleiter TC 1997 56 1-2 47-54 Veterinary microbiology Katayama et al., 1997 journal Katayama S, Okada N, Yoshiki K, Okabe T, Shimizu Y 1997 59 8 657-663 The Journal of veterinary medical science / the Japanese Society of Veterinary Science Kimman et al., 1994 journal Kimman TG, De Wind N, De Bruin T, de Visser Y, Voermans J 1994 205 2 511-518 Virology Matsuda et al., 1992 journal Matsuda Tsuchida A, Katayama S, Okada N, Okabe T, Sasaki N 1992 54 3 447-452 The Journal of veterinary medical science / the Japanese Society of Veterinary Science Merck Vet Manual: Pseudorabies website http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/102200.htm Peeters et al., 1994 journal Peeters B, Bouma A, de Bruin T, Moormann R, Gielkens A, Kimman T 1994 12 4 375-380 Vaccine Shiau et al., 2001 journal Shiau AL, Chu CY, Su WC, Wu CL 2001 19 23-24 3277-3284 Vaccine Vrublevskaia et al., 2007 journal Vrublevskaia VV, Musienko VS, Skarga IuIu, Morenkov OS 2007 52 3 33-37 Voprosy virusologii Weigel et al., 2003 journal Weigel RM, Hahn EC, Scherba G 2003 92 1-2 19-24 Veterinary microbiology Wiki: Pseudorabies website http://en.wikipedia.org/wiki/Pseudorabies